Company intelligence / Profile preview

Beijing Changjiang Pharmaceutical Development Foundation

Dongguan, Guangdong, China

Ownership: Private
Employees: ~4860
Development stage: Other

Overview

YiChang HEC ChangJiang Pharmaceutical is a leading Chinese pharmaceutical company with over 20 years of history. It has commercialized more than 30 products across anti-infective, metabolic/endocrine, and cardiovascular areas. Its flagship product is oseltamivir phosphate ("Kewei"), a first-line antiviral for influenza in China. The company continues to expand its pipeline through internal R&D and partnerships.

Therapeutic areas: RheumatologyCardiovascularInfectious DiseasesEndocrinology
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Sunshine Lake Pharma—R&D pipeline cooperation agreement signed November 2023

Beyond the preview

Go deeper on Beijing Changjiang Pharmaceutical Development Foundation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Changjiang Pharmaceutical Development Foundation.

Explore the full profile